Since the establishment of operations in China in the early 1980s, Pfizer is committed to long-term development and introducing innovative medicine into China.

In the meantime, Pfizer is a leader in corporate social responsibility and supports healthcare reforms and development with investment in infrastructure and capacity building and ongoing physician and patient education campaigns, as well as community philanthropy programmes.

Pfizer has four state-of-the-art plants in Dalian, Suzhou and Wuxi. Built in 1989, the Dalian Plant is the first pharmaceutical manufacturing facility to receive Good Manufacturing Practice (GMP).

To implement long-term development, Pfizer established the Beijing Management Centre in 1997. In 2004 and 2005, Pfizer also set up the China Regional Headquarters, Pfizer Investment Co Ltd and Pfizer China R&D Centre respectively in Shanghai.

Pfizer maintains a business presence in over 50 cities and 1,800 personnel are working for healthcare in China. Pfizer is one of the major investors in pharmaceuticals in China with a total investment of over US$500 million.

Pfizer manufactures and markets many of the world's leading medications in China. Pfizer is distinctive in China as it aims to make its newly developed medications available to Chinese patients at the same time they are introduced to global markets.

With an unequalled product portfolio, Pfizer maintains category leadership in the therapeutic areas of cardiovascular, endocrinology, neuroscience, infectious disease, urology, ophthalmology, oncology arthritis and other inflammatory diseases. Looking to the future, Pfizer will introduce 20 more innovative products in China by 2010.

For more information, please visit:www.pfizer.com.cn

(China Daily 07/26/2006 page9)